Leptomeningeal Metastases Market to Register Modest Growth at a CAGR of 1.9% During 2025–2034 | DelveInsight
The leptomeningeal metastases market is anticipated to witness gradual expansion over the forecast period, primarily driven by the rising global burden of cancer and the growing occurrence of central nervous system (CNS) complications in patients with advanced-stage malignancies. Furthermore, the introduction of promising therapies such as Rhenium-186 obisbemeda (REYOBIQ), Paxalisib, HSV G2072, AZD1390, and others is expected to contribute significantly to market development in the coming years.
According to DelveInsight’s comprehensive Leptomeningeal Metastases Market Insights report, the study offers a detailed evaluation of existing treatment practices, emerging drug candidates, individual therapy market shares, and both historical and projected market sizes from 2020 to 2034. The analysis spans key regions, including the United States, EU4 (Germany, Italy, France, and Spain), the United Kingdom, and Japan.
The global market for leptomeningeal metastases treatment reached approximately USD 1.7 billion in 2024 and is projected to demonstrate steady growth across major markets through 2034. The United States represents the largest share of the leptomeningeal metastases market, accounting for nearly 60%, compared to EU4 countries, the UK, and Japan. In 2024, the total number of incident cases of leptomeningeal metastases across leading markets was estimated to be around 300K. Key leptomeningeal metastases companies, including Plus Therapeutics, Kazia Therapeutics, Genentech, Treovir, AstraZeneca, Angiochem, as well as Asian innovators such as Chugai Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, Yuhan Corporation, and
Takeda Pharmaceutical, are actively working on innovative leptomeningeal metastases drugs. Some of the key leptomeningeal metastases therapies in clinical trials include Rhenium-186 obisbemeda (REYOBIQ), Paxalisib, HSV G2072, AZD1390, ANG1005, trastuzumab deruxtecan, patritumab deruxtecan, lazertinib, and osimertinib. These novel leptomeningeal metastases therapies are anticipated to enter the leptomeningeal metastases market in the forecast period and are expected to change the market.
Discover which leptomeningeal metastases medications are expected to grab the market share @ Leptomeningeal Metastases Market Report
Rising Incidence of Central Nervous System Metastases Advances in cancer treatment have significantly improved patient survival rates, which has inadvertently led to an increase in CNS-related complications such as leptomeningeal metastases. As patients live longer with cancer, the likelihood of disease progression into the central nervous system rises, expanding the population requiring specialized care. In the United States alone, approximately 120K new cases of leptomeningeal metastases were reported in 2024, underscoring the severity of the condition and the urgent need for better diagnostic and therapeutic solutions.
Despite the growing burden, there remains a lack of FDA-approved therapies specifically designed for leptomeningeal metastases. Diagnosis is often delayed due to inadequate screening tools and non-specific symptoms. This gap highlights a substantial opportunity for pharmaceutical innovation, particularly in developing treatments capable of overcoming challenges such as the blood–brain barrier and achieving effective drug delivery into cerebrospinal fluid.
The pipeline for leptomeningeal metastases treatments is gaining traction, with several innovative approaches under investigation. For example, Plus Therapeutics is developing Rhenium (186Re) Obisbemeda, a targeted radiotherapy currently in clinical trials. Additionally, antibody-drug conjugates such as patritumab deruxtecan and trastuzumab deruxtecan have shown encouraging results, offering potential breakthroughs for patients who currently have limited treatment options. EGFR-targeted therapies such as osimertinib and lazertinib have also demonstrated strong CNS penetration and clinical activity in leptomeningeal disease.
Although the disease burden is considerable, there are still no therapies explicitly approved for leptomeningeal metastases. Current treatment approaches are largely palliative, focusing on symptom management and slowing disease progression. Commonly used off-label medications include methotrexate, cytarabine, temozolomide, capecitabine, topotecan, and lapatinib, often administered alongside radiation therapy. These strategies aim to maintain neurological function and improve quality of life rather than provide a cure.
The United States dominated the leptomeningeal metastases market in 2024, contributing nearly 60% of total revenue. This dominance is driven by extensive use of advanced therapies, including systemic, targeted, intrathecal, and radiation-based treatments. Favorable reimbursement systems, rapid adoption of innovative therapies, and access to advanced healthcare infrastructure further strengthen the US market position.
Pharmaceutical companies have historically played a limited role in leading large-scale development programs in this space. Instead, many have supported academic research through investigational drug contributions and partial funding. However, certain companies stand out—Plus Therapeutics is actively advancing REYOBIQ, while Angiochem previously developed ANG1005, a peptide-drug conjugate capable of crossing both the blood–brain and blood–CSF barriers, although its development is currently paused. At the same time, Asian companies are gaining traction through CNS-penetrant targeted therapies and antibody-drug conjugates, particularly in EGFR- and HER2-driven cancers.
The development landscape has also faced setbacks. For instance, Omburtamab, developed by Y-mAbs Therapeutics as a radiolabeled monoclonal antibody targeting B7-H3, completed late-stage trials but received a Complete Response Letter from the FDA in 2022 due to insufficient clinical benefit and concerns related to study design. Such challenges highlight the complexity of developing effective therapies for this condition.
Learn more about the leptomeningeal metastases treatment options @ Leptomeningeal Metastases Treatment Guidelines
The competitive environment includes several promising therapies currently in clinical trials, such as REYOBIQ (Plus Therapeutics), Paxalisib (Kazia Therapeutics/Genentech), HSV G2072 (Treovir), AZD1390 (AstraZeneca), ANG1005 (Angiochem), along with emerging agents from Asian companies including trastuzumab deruxtecan and patritumab deruxtecan (Daiichi Sankyo/Chugai), lazertinib (Yuhan Corporation), osimertinib (AstraZeneca), and nivolumab (Ono Pharmaceutical).
REYOBIQ (rhenium Re186 obisbemeda) is an innovative injectable radiotherapy designed to deliver targeted, high-dose radiation directly to CNS tumors. Its unique properties - such as a short half-life, beta emissions for tumor destruction, and gamma emissions for imaging - make it a compelling candidate for treating leptomeningeal metastases. It is currently being evaluated in the ReSPECT-LM clinical trial.
Paxalisib (GDC-0084) is another investigational therapy aimed at treating brain cancers. It inhibits the PI3K/Akt/mTOR signaling pathway, which plays a crucial role in cell growth and survival. Its ability to cross the blood–brain barrier makes it particularly effective for CNS malignancies, addressing one of the major challenges in treating leptomeningeal metastases.
The expected approval and commercialization of these therapies could significantly transform the treatment landscape. As these drugs progress through clinical development and potentially gain regulatory approval, they are likely to introduce new standards of care, enhance patient outcomes, and create new growth opportunities within the market.
To know more about new treatment for leptomeningeal metastases, visit @ Leptomeningeal Metastases Management
Leptomeningeal metastases, also known as carcinomatous or neoplastic meningitis, occur when cancer cells spread to the cerebrospinal fluid and the membranes surrounding the brain and spinal cord. These malignant cells may originate from primary CNS tumors or metastasize from cancers elsewhere in the body through the bloodstream.
The leptomeningeal metastases market report provides a detailed epidemiological analysis covering the period from 2020 to 2034 across major markets. In 2024, approximately 300K cases were reported across the seven major markets (7MM), indicating a substantial disease burden. The United States accounted for nearly 40% of these cases, making it the largest contributor.
Download the report to understand which factors are driving leptomeningeal metastases epidemiology trends @ Leptomeningeal Metastases Treatment Algorithm
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Related report
Leptomeningeal Metastases - Epidemiology Forecast - 2034
DelveInsight’s “Leptomeningeal Metastases – Epidemiology Forecast – 2034” report delivers an in-depth understanding of leptomeningeal metastases, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Leptomeningeal Metastases Companies developing therapies include - Plus Therapeutics, Kazia Therapeutics, Genentech, and others.
Leptomeningeal Metastases - Pipeline Insight, 2026
DelveInsight’s, “Leptomeningeal Metastases - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Leptomeningeal Metastases pipeline landscape. The leading Leptomeningeal Metastases Companies developing therapies include - Plus Therapeutics, Kazia Therapeutics, Genentech, and others.
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com